Recent advances in antimicrobial therapy.
Metronidazole is a relatively nontoxic, oral agent which may prove to be useful in the treatment of infections caused by susceptible anaerobic organisms. Use of metronidazole to treat anaerobic infections presently is investigational.
D000583:Amikacin / Q000494:pharmacology / Q000627:therapeutic use; D000658:Amoxicillin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use; D002981:Clindamycin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use; D012853:Sisomicin / Q000031:analogs & derivatives / Q000494:pharmacology; D000198:Spectinomycin / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000494:pharmacology / Q000627:therapeutic use; D013982:Ticarcillin / Q000494:pharmacology / Q000627:therapeutic use; D014031:Tobramycin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D008795:Metronidazole; D002981:Clindamycin; D000658:Amoxicillin; D000583:Amikacin; D000198:Spectinomycin; D014295:Trimethoprim; D013982:Ticarcillin; D013420:Sulfamethoxazole; D014031:Tobramycin; D012853:Sisomicin